MetaShape reports preclinical MS 001 data with GLP-1 drugs

MetaShape Pharma presented preclinical data at the ADA 2026 Scientific Sessions in New Orleans showing MS 001 boosted semaglutide and tirzepatide outcomes in obese mice. The company says the oral co-therapy may improve weight loss, preserve muscle and reduce regain, while it prepares to move the program toward clinical development.

Why it matters: - MetaShape Pharma is trying to solve some of the biggest limits of GLP-1 obesity drugs: muscle loss, plateaus, weaker responses in heavier patients and weight regain after treatment stops. - The company says MS 001 could help GLP-1 therapies produce deeper and more durable weight loss without relying on lower food intake. - The program could matter beyond obesity, since MetaShape says the mechanism may also have applications in cardiometabolic and neuroinflammatory diseases.

What happened: - MetaShape Pharma AG presented new preclinical data on MS 001 at the 2026 Scientific Sessions of the American Diabetes Association, held June 5-8 in New Orleans. - The studies tested MS 001 in combination with semaglutide and with tirzepatide. - The poster is available on the MetaShape website.

The details: - MS 001 is an oral small-molecule drug designed to amplify GLP-1 therapies. - In diet-induced obese mice, low-dose MS 001 plus semaglutide reduced white adipose tissue, increased muscle weight versus vehicle and semaglutide, and lowered cholesterol and triglycerides. - The combination also drove deeper weight loss without reducing caloric intake. - MS 001 reduced weight regain after GLP-1 discontinuation and produced greater weight reduction in animals with higher baseline body weight. - RNA sequencing showed the strongest transcriptional changes in white adipose tissue with semaglutide plus MS 001 versus semaglutide alone. - KEGG pathway analysis showed activation of calcium and glucagon signaling pathways linked to thermogenesis. - Thermal imaging showed increased adipose tissue thermogenesis in animals receiving tirzepatide plus MS 001 versus tirzepatide alone. - MetaShape says these findings suggest MS 001 increases adipose tissue metabolism and fat breakdown while preserving muscle mass. - MS 001, or ulodesine hemiglutarate, is an oral inhibitor of purine nucleoside phosphorylase in pre-IND development. - MetaShape says ulodesine has been administered to more than 500 subjects in clinical studies and was generally safe and well tolerated. - The company says MS 001 is a patent-pending salt form of ulodesine. - MetaShape is preparing a Series A financing of $10 million to advance MS 001 through clinical proof of concept. - The company expects initial efficacy data in 2029.

Between the lines: - The data point to a combination strategy rather than a replacement for GLP-1 medicines. - By emphasizing fat-selective weight loss and muscle preservation, MetaShape is targeting outcomes that could improve the real-world value of obesity treatment. - The company is also framing MS 001 as a metabolic amplifier, which could help differentiate it from drugs that mainly reduce appetite. - The results are preclinical, so the key question is whether the same benefits appear in people.

What’s next: - MetaShape plans to move MS 001 into clinical development for obesity and cardiometabolic disorders. - The company is seeking Series A funding to support clinical proof of concept. - Investors and clinicians will be looking for human data that confirm the weight-loss, muscle-preserving and durability signals seen in animals.

The bottom line: - MetaShape is betting that the next advance in obesity care will come from pairing GLP-1 drugs with a co-therapy that shifts metabolism toward more fat burning and less muscle loss.